Rigel Pharmaceuticals
Gregg Lapointe is the current director at Rigel Pharmaceuticals. Prior to this, they served as the chief executive officer of Sigma-Tau Pharmaceuticals, Inc. from 2007 to 2012. Gregg has also held the position of vice president, finance at Sigma-Tau Pharmaceuticals, Inc. from 2001 to 2002. Other notable positions include vice president & controller at AstenJohnson Inc. from 2000 to 2001 and vice president of operations at JWI Ltd. from 1996 to 1999. Gregg Lapointe began their career as an auditor at PricewaterhouseCoopers (formerly Price Waterhouse) in 1982 and remained there until 1989.
Gregg Lapointe has an MBA from Duke University - The Fuqua School of Business, a Graduate Diploma in Public Accounting from McGill University, and a Bachelor of Commerce from Concordia University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Rigel Pharmaceuticals
3 followers
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel, small-molecule drugs for the treatment of immune diseases and cancers.